Treace Medical Concepts (TMCI) Gets a Hold from Stifel Nicolaus
Treace Medical Concepts (TMCI) received a Hold rating from Stifel Nicolaus, with a price target of $5.00, as reported by analyst Rick Wise. Wise, a 3-star analyst, has a 50.60% success rate. Additionally, BTIG's Ryan Zimmerman also issued a Hold rating, while J.P. Morgan downgraded TMCI to a Sell on the same day.
In a report released today, Rick Wise from Stifel Nicolaus maintained a Hold rating on Treace Medical Concepts, with a price target of $5.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
According to TipRanks, Wise is a 3-star analyst with an average return of 1.0% and a 50.60% success rate. Wise covers the Healthcare sector, focusing on stocks such as Artivion, Solventum Corporation, and Edwards Lifesciences.
In addition to Stifel Nicolaus, Treace Medical Concepts also received a Hold from BTIG’s Ryan Zimmerman in a report issued today. However, on the same day, J.P. Morgan downgraded Treace Medical Concepts (NASDAQ: TMCI) to a Sell.
